Dapagliflozin
Författaruppgift saknas
Journal missing · review PUBLICATION REGISTRY
Go to research.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för dapagliflozin. Visa hela publikationsregistret
A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publications in the selection
47 hitsDapagliflozin in patients with myocardial infarction without diabetes or prior heart failure.
James S, Storey RF, Oldgren J.
Eur Heart J Cardiovasc Pharmacother · journal article · DOI 10.1093/ehjcvp/pvad096Dapagliflozin Does Not Protect against Adriamycin-Induced Kidney Injury in Mice.
Cha JJ, Park HJ, Yoo JA, Ghee J, Cha DR, Kang YS.
Kidney Blood Press Res · journal article · DOI 10.1159/000536088Acute antiarrhythmic effects of SGLT2 inhibitors-dapagliflozin lowers the excitability of atrial cardiomyocytes.
Paasche A, Wiedmann F, Kraft M, Seibertz F, Herlt V, Blochberger PL, Jávorszky N, Beck M, Weirauch L, Seeger T, Blank A, Haefeli WE, Arif R, Meyer AL, Warnecke G, Karck M, Voigt N, Frey N, Schmidt C.
Basic Res Cardiol · research support, non-u.s. gov't; research-article; journal article · DOI 10.1007/s00395-023-01022-0How to Demonstrate the Impact of Dapagliflozin on Improving Hyperuricemia in Patients with Chronic Kidney Disease.
Fujioka H, Kataoka N, Imamura T.
Intern Med · letter; journal article · DOI 10.2169/internalmedicine.2725-23Dapagliflozin in patients with critical illness: rationale and design of the DEFENDER study.
Tavares CAM, Azevedo LCP, Rea-Neto Á, Campos NS, Amendola CP, Bergo RR, Kozesinski-Nakatani AC, David-João PG, Westphal GA, Guimarães Júnior MRR, Lobo SMA, Tavares MS, Dracoulakis MDA, Souza GM, Almeida GMB, Gebara OCE, Tomba PO, Albuquerque CSN, Silva MCR, Pereira AJ, Damiani LP, Corrêa TD, Serpa-Neto A, Berwanger O, Zampieri FG.
Crit Care Sci · clinical trial protocol; research-article; journal article · DOI 10.5935/2965-2774.20230129-enDapagliflozin administration for 1 year promoted kidney enlargement in patient with ADPKD.
Nakatani S, Morioka F, Uedono H, Tsuda A, Mori K, Emoto M.
CEN Case Rep · journal article; case reports; case-report · DOI 10.1007/s13730-023-00840-4Type 2 diabetes mellitus pharmacological remission with dapagliflozin plus oral semaglutide.
Lunati ME, Cimino V, Bernasconi D, Gandolfi A, Morpurgo PS, Tinari C, Lazzaroni E, Baruffaldi L, Muratori M, Montefusco L, Pastore I, Rossi A, Franzetti IG, Muratori F, Manfrini R, Disoteo OE, Terranova R, Desenzani P, Girelli A, Ghelardi R, D'Addio F, Ben Nasr M, Berra C, Folli F, Bucciarelli L, Fiorina P.
Pharmacol Res · journal article; observational study · DOI 10.1016/j.phrs.2023.107040Dapagliflozin Ameliorates Neural Damage in the Heart and Kidney of Diabetic Mice.
Donoiu I, Târtea G, Sfredel V, Raicea V, Țucă AM, Preda AN, Cozma D, Vătășescu R.
Biomedicines · research-article; journal article · DOI 10.3390/biomedicines11123324Effects of Dapagliflozin in Chronic Kidney Disease Across the Spectrum of Age and by Sex.
Yu MK, Vart P, Jongs N, Correa-Rotter R, Rossing P, McMurray JJV, Hou FF, Douthat W, Khullar D, Langkilde AM, Wheeler DC, Heerspink HJL, Chertow GM.
J Gen Intern Med · research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1007/s11606-023-08397-9Retracted: Efficacy of Dapagliflozin Combined with Lifestyle Intervention in Obesity Control.
Methods In Medicine CAM.
Comput Math Methods Med · retraction of publication; retraction notice · DOI 10.1155/2023/9780164Effect of dapagliflozin on proteomics and metabolomics of serum from patients with type 2 diabetes.
Liu J, Chang X, Ding X, He X, Wang J, Wang G.
Diabetol Metab Syndr · research-article; journal article · DOI 10.1186/s13098-023-01229-0The dapagliflozin in patients with myocardial infarction (DAPA-MI) trial in perspective.
Rossello X, Rubini Gimenez M.
Eur Heart J Acute Cardiovasc Care · journal article · DOI 10.1093/ehjacc/zuad142SGLT2 inhibitor dapagliflozin protects the kidney in a murine model of Balkan nephropathy.
Oe Y, Kim YC, Sidorenko VS, Zhang H, Kanoo S, Lopez N, Goodluck HA, Crespo-Masip M, Vallon V.
Am J Physiol Renal Physiol · research support, non-u.s. gov't; research-article; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1152/ajprenal.00228.2023Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.
Koshino A, Neuen BL, Jongs N, Pollock C, Greasley PJ, Andersson EM, Hammarstedt A, Karlsson C, Langkilde AM, Wada T, Heerspink HJL.
Cardiovasc Diabetol · research support, non-u.s. gov't; research-article; randomized controlled trial; journal article · DOI 10.1186/s12933-023-02027-8Analysing uric acid levels to assess the effectiveness of dapagliflozin.
Rajasekar R, Sundaram SM, Raj CP, Poovitha M, Kumar JS.
Clin Nutr ESPEN · journal article · DOI 10.1016/j.clnesp.2023.11.013Zibotentan in combination with dapagliflozin compared with dapagliflozin in patients with chronic kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, phase 2b, clinical trial.
Heerspink HJL, Kiyosue A, Wheeler DC, Lin M, Wijkmark E, Carlson G, Mercier AK, Åstrand M, Ueckert S, Greasley PJ, Ambery P.
Lancet · clinical trial, phase ii; research support, non-u.s. gov't; multicenter study; randomized controlled trial; journal article · DOI 10.1016/s0140-6736(23)02230-4Correction to: Effect of dapagliflozin on COVID-19 infection and risk of hospitalization.
Författaruppgift saknas
J Antimicrob Chemother · published erratum; correction · DOI 10.1093/jac/dkad305The effect of Dapagliflozin on renal functions in hospitalized patients with Acute Heart Failure.
Gilani SFF, Ali S, Siddique MB, Farhat K, Noor M, Waqar F.
Pak J Med Sci · research-article; journal article · DOI 10.12669/pjms.39.6.7525Efficacy and safety of dapagliflozin for treating heart failure in China: A meta-analysis.
Wu W, Yao S, Xu Q, Cheng H, Jiang Q.
Pak J Pharm Sci · meta-analysis; systematic review; journal articleDapagliflozin/Hesperidin Combination Mitigates Lipopolysaccharide-Induced Alzheimer's Disease in Rats.
Abd Elmaaboud MA, Estfanous RS, Atef A, Kabel AM, Alnemari KA, Naguib TM, Alsufyani SE, Darwish HW, Arab HH.
Pharmaceuticals (Basel) · research-article; journal article · DOI 10.3390/ph16101370Effect of dapagliflozin on COVID-19 infection and risk of hospitalization.
Salgado-Barreira A, Seijas-Amigo J, Rodriguez-Mañero M, Piñeiro-Lamas M, Eiras S, Cordero A, Gonzalez-Juanatey JR, Figueiras A.
J Antimicrob Chemother · research support, non-u.s. gov't; research-article; journal article · DOI 10.1093/jac/dkad241Dapagliflozin impedes endothelial cell senescence by activating the SIRT1 signaling pathway in type 2 diabetes.
Tai S, Zhou Y, Fu L, Ding H, Zhou Y, Yin Z, Yang R, Liu Z, Zhou S.
Heliyon · research-article; journal article · DOI 10.1016/j.heliyon.2023.e19152A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects.
Kim HC, Lee S, Sung S, Kim E, Jang IJ, Chung JY.
Drug Des Devel Ther · randomized controlled trial; journal article; case-report · DOI 10.2147/dddt.s404182Effects of dapagliflozin in the progression of atherosclerosis in patients with type 2 diabetes: a meta-analysis of randomized controlled trials.
Wu QL, Zheng T, Li SZ, Chen JA, Xie ZC, Lai JM, Zeng JY, Lin JT, Huang JS, Lin MH.
Diabetol Metab Syndr · review-article; review; journal article · DOI 10.1186/s13098-022-00810-3Dapagliflozin in Patients with Chronic Heart Failure: A Systematic Review and Meta-Analysis.
Cai RP, Xu YL, Su Q.
Cardiol Res Pract · review-article; review; journal article · DOI 10.1155/2021/6657380Simultaneous Estimation of Saxagliptin and Dapagliflozin in Human Plasma by Validated High Performance Liquid Chromatography - Ultraviolet Method.
Donepudi S, Achanta S.
Turk J Pharm Sci · research-article; journal article · DOI 10.4274/tjps.galenos.2018.46547Dapagliflozin: a new sodium-glucose cotransporter 2 inhibitor for treatment of type 2 diabetes.
Vivian EM.
Am J Health Syst Pharm · research support, non-u.s. gov't; review; journal article · DOI 10.2146/ajhp140168Selective reaction monitoring of negative electrospray ionization acetate adduct ions for the bioanalysis of dapagliflozin in clinical studies.
Ji QC, Xu X, Ma E, Liu J, Basdeo S, Liu G, Mylott W, Boulton DW, Shen JX, Stouffer B, Aubry AF, Arnold ME.
Anal Chem · journal article · DOI 10.1021/ac5037523Dapagliflozin lowers plasma glucose concentration and improves β-cell function.
Merovci A, Mari A, Solis-Herrera C, Xiong J, Daniele G, Chavez-Velazquez A, Tripathy D, Urban McCarthy S, Abdul-Ghani M, DeFronzo RA.
J Clin Endocrinol Metab · research-article; randomized controlled trial; research support, u.s. gov't, non-p.h.s.; journal article; research support, n.i.h., extramural · DOI 10.1210/jc.2014-3472